Skip to main content

Sherwin Stephen A's Form 4 filing

Neurocrine Biosciences IncNBIX · filed May 30, 2024

Accession no.
0000914475-24-000160
Filed
May 30, 2024
Trade date
May 29, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.34M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sherwin Stephen ACIK 0001079462Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 29, 2024Common StockMOption exerciseAcquired+25,000$42.76+$1,069,00051,504Direct
May 29, 2024Common StockSSaleDisposed−25,000$133.46F2−$3,336,50026,504Direct
May 29, 2024Common StockMOption exerciseAcquired+15,000$47.89+$718,35041,504Direct
May 29, 2024Common StockSSaleDisposed−15,000$133.47F3−$2,002,05026,504Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 29, 2024Common StockMOption exerciseDisposed−25,000$0.00$00Direct
May 29, 2024Common StockMOption exerciseDisposed−15,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.22 to $136.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

F3

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.00 to $136.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)